公开(公告)号：US20170114075A1

公开(公告)日：2017-04-27

申请号：US15253369

申请日：2016-08-31

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Mikhail Chafeev ,  Sultan Chowdhury ,  Lauren Fraser ,  Jianmin Fu ,  Jonathan Langille ,  Shifeng Liu ,  Jianyu Sun ,  Shaoyi Sun ,  Serguei Sviridov ,  Mark Wood ,  Alla Yurevna Zenova ,  Qi Jia ,  Jean-Jacques Alexandre Cadieux ,  Simon J. Gauthier ,  Amy Frances Douglas ,  Tom Hsieh ,  Nagasree Chakka ,  Zoran Cikojevic

IPC: C07D513/22 ,  C07D491/20 ,  C07D495/20 ,  C07D498/20 ,  C07D491/22 ,  C07D513/20 ,  C07D491/107

CPC classification number: C07D513/22 ,  C07D491/10 ,  C07D491/107 ,  C07D491/20 ,  C07D491/22 ,  C07D495/20 ,  C07D498/20 ,  C07D513/20 ,  C07D519/00

Abstract: This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

公开(公告)号：US11091441B2

公开(公告)日：2021-08-17

申请号：US17069386

申请日：2020-10-13

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Paul Robert Bichler ,  Jean-Jacques Alexandre Cadieux ,  Matthew David Tandy ,  Gregory N. Beatch

IPC: C07D217/04

Abstract: The present disclosure provides solid state forms of a selective potassium channel modulator and pharmaceutical compositions comprising the solid state crystalline forms and pharmaceutically acceptable excipients, and methods for preparing and using the solid state forms and the pharmaceutical compositions thereof.

公开(公告)号：US09695185B2

公开(公告)日：2017-07-04

申请号：US14989600

申请日：2016-01-06

Applicant: XENON PHARMACEUTICALS INC.

Inventor： Jean-Jacques Alexandre Cadieux ,  Mikhail Chafeev ,  Sultan Chowdhury ,  Jianmin Fu ,  Qi Jia ,  Stefanie Abel ,  Emad El-Sayed ,  Elke Huthmann ,  Thomas Isarno

IPC: C07D491/20 ,  C07D405/04

CPC classification number: C07D491/20 ,  C07D405/04

Abstract: This invention is directed to methods of preparing certain spiro-oxindole derivatives, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

公开(公告)号：US20170073351A1

公开(公告)日：2017-03-16

申请号：US15278759

申请日：2016-09-28

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Mikhail Chafeev ,  Jianmin Fu ,  Jean-Jacques Alexandre Cadieux

IPC: C07D491/20 ,  C07B57/00

CPC classification number: C07D491/20 ,  A61K31/407 ,  C07B57/00 ,  C07B2200/07 ,  C07D491/22

Abstract: This invention is directed to the (S)-enantiomer of the compound of formula (I): or a pharmaceutically acceptable solvate or prodrug thereof. This (S)-enantiomer is useful for the treatment of diseases or conditions, such as pain, which are ameliorated or alleviated by the modulation of voltage-gated sodium channels.

Abstract translation: 或其药学上可接受的溶剂合物或前药。 该（S） - 对映体可用于治疗通过调节电压门控钠通道而改善或缓解的疾病或病症，例如疼痛。

公开(公告)号：US09458178B2

公开(公告)日：2016-10-04

申请号：US14542367

申请日：2014-11-14

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Mikhail Chafeev ,  Sultan Chowdhury ,  Lauren Fraser ,  Jianmin Fu ,  Jonathan Langille ,  Shifeng Liu ,  Jianyu Sun ,  Shaoyi Sun ,  Serguei Sviridov ,  Mark Wood ,  Alla Yurevna Zenova ,  Qi Jia ,  Jean-Jacques Alexandre Cadieux ,  Simon J. Gauthier ,  Amy Frances Douglas ,  Tom Hsieh ,  Nagasree Chakka ,  Zoran Cikojevic

IPC: C07D513/20 ,  C07D491/10 ,  C07D491/107 ,  C07D491/20 ,  C07D491/22 ,  C07D495/20 ,  C07D498/20 ,  C07D519/00

CPC classification number: C07D513/22 ,  C07D491/10 ,  C07D491/107 ,  C07D491/20 ,  C07D491/22 ,  C07D495/20 ,  C07D498/20 ,  C07D513/20 ,  C07D519/00

Abstract: This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

Abstract translation: 本发明涉及螺 - 羟吲哚化合物，作为立体异构体，对映体，其互变异构体或其混合物; 或其药学上可接受的盐，溶剂合物或前药用于治疗和/或预防钠通道介导的疾病或病症，例如疼痛。

公开(公告)号：US08916580B2

公开(公告)日：2014-12-23

申请号：US13787558

申请日：2013-03-06

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Mikhail Chafeev ,  Sultan Chowdhury ,  Lauren Fraser ,  Jianmin Fu ,  Jonathan Langille ,  Shifeng Liu ,  Jianyu Sun ,  Shaoyi Sun ,  Serguei Sviridov ,  Mark Wood ,  Alla Yurevna Zenova ,  Qi Jia ,  Jean-Jacques Alexandre Cadieux ,  Simon J. Gauthier ,  Amy Frances Douglas ,  Tom Hsieh ,  Nagasree Chakka ,  Zoran Cikojevic

IPC: A61K31/44 ,  C07D491/107 ,  C07D491/10 ,  C07D491/22 ,  C07D491/20 ,  C07D498/20 ,  C07D495/20 ,  C07D513/20

CPC classification number: C07D513/22 ,  C07D491/10 ,  C07D491/107 ,  C07D491/20 ,  C07D491/22 ,  C07D495/20 ,  C07D498/20 ,  C07D513/20 ,  C07D519/00

Abstract: This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

Abstract translation: 本发明涉及螺 - 羟吲哚化合物，作为立体异构体，对映体，其互变异构体或其混合物; 或其药学上可接受的盐，溶剂合物或前药用于治疗和/或预防钠通道介导的疾病或病症，例如疼痛。